Displaying One Session

Room Scene AB 05.03.2018 15:20 - 16:50
Date
05.03.2018
Time
15:20 - 16:50
Location
Room Scene AB
Chairs
  • Vincent Ribrag (Villejuif, FR)
  • Anas Younes (New York, US)
New concepts and new targets in haematology early drug development Educational session

10IN - Introduction and Metabolism interference or epigenetics treatment with special focus on haematological diseases

Presentation Number
10IN
Lecture Time
15:20 - 15:50
Speakers
  • Tak Mak (Toronto, CA)
Location
Room Scene AB, Paris Marriott Rive Gauche, Paris, France
Date
05.03.2018
Time
15:20 - 16:50
Authors
  • Tak Mak (Toronto, CA)
New concepts and new targets in haematology early drug development Educational session

11IN - Genomic-guided trials in lymphoma

Presentation Number
11IN
Lecture Time
15:50 - 16:05
Speakers
  • Anas Younes (New York, US)
Location
Room Scene AB, Paris Marriott Rive Gauche, Paris, France
Date
05.03.2018
Time
15:20 - 16:50
Authors
  • Anas Younes (New York, US)
New concepts and new targets in haematology early drug development Educational session

12IN - Genomic-guided metabolism drug development in myeloid diseases

Presentation Number
12IN
Lecture Time
16:05 - 16:20
Speakers
  • David Schenkein (Cambridge, US)
Location
Room Scene AB, Paris Marriott Rive Gauche, Paris, France
Date
05.03.2018
Time
15:20 - 16:50
Authors
  • David Schenkein (Cambridge, US)

Abstract

Background

Mutations in isocitrate dehydrogenase (IDH)1 or IDH2 are seen in ~15–20% of patients with acute myeloid leukemia (AML). Mutant IDH (mIDH) reduces α-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG), leading to histone hypermethylation and a block in myeloid differentiation. Ivosidenib (AG-120) and enasidenib (AG-221) are potent, selective, oral small molecule inhibitors of mIDH1 and mIDH2, respectively. Both have been shown preclinically to reduce aberrant 2-HG levels and promote myeloid differentiation, and as monotherapy are associated with robust overall response rates in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Enasidenib received full approval in the United States in Aug 2017 for the treatment of adult patients with R/R AML with an IDH2 mutation. A New Drug Application was recently submitted to the FDA for ivosidenib for the treatment of patients with R/R AML and an IDH1 mutation, based on evidence in patients showing clinical activity and observation of clinical benefit, including achievement of transfusion independence, and a decrease in the frequency of comorbidities such as febrile neutropenia and infections in responding patients. Additional data demonstrate that ivosidenib monotherapy results in deep IDH1 mutation clearance in a subset of patients with R/R AML and untreated AML who achieve clinical response. Tolerability and preliminary clinical activity data were also recently presented from two Phase 1 studies evaluating ivosidenib and enasidenib in combination with standard induction (7+3) chemotherapy or azacitadine in newly diagnosed AML patients. Independent clinical trials are currently underway for ivosidenib in mIDH1-positive malignancies in the solid tumor context. This presentation will focus on the discovery of these investigational medicines, as well as the promising clinical and translational results from the hematologic malignancy and solid tumor trials.

Legal entity responsible for the study

Agios Pharmaceuticals, Inc.

Disclosure

D. Schenkein: Agios: Full time employee, stock ownership, board of directors. Bluebird Bio: board of directors. Denali Therapeutics: board of directors.

Funding

Agios Pharmaceuticals, Inc.

Collapse
New concepts and new targets in haematology early drug development Educational session

13IN - Personalized therapy in adult acute lymphocytic leukemia: Path to the cure

Presentation Number
13IN
Lecture Time
16:20 - 16:35
Speakers
  • Elias Jabbour (Houston, US)
Location
Room Scene AB, Paris Marriott Rive Gauche, Paris, France
Date
05.03.2018
Time
15:20 - 16:50
Authors
  • Elias Jabbour (Houston, US)
New concepts and new targets in haematology early drug development Educational session

Q&A / Panel Discussion

Lecture Time
16:35 - 16:50
Location
Room Scene AB, Paris Marriott Rive Gauche, Paris, France
Date
05.03.2018
Time
15:20 - 16:50